[Lupus nephropathy treated with cyclosporine A. Report of 3 cases].
Three patients are reported who had systemic lupus erythematosus and membrane-proliferative glomerulonephritis. These patients failed to respond to intravenous cyclophosphamide and steroids and were then changed to receive oral cyclosporine A, at a dose of 5 mg/kg/day. The three patients showed remission of disease, symptoms, and renal and immunological parameters, with minimal secondary effects. The medical literature was reviewed and cyclosporine A is suggested to be a therapeutical choice for patients with lupus nephropathy even when they do not respond to other immunosuppressive regimes, such as pulse cyclophosphamide.
García Gasalla
M
M
Servicio de Medicina Interna I, Clínica Puerta de Hierro, Madrid.
Yebra Bango
M
M
Vargas Núñez
J A
JA
López García
E
E
Villarreal García-Lomas
M
M
Durántez Martínez
A
A
D000328:Adult; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D015432:Glomerulonephritis, Membranoproliferative / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*
D007166:Immunosuppressive Agents; D016572:Cyclosporine
Nefropatía lúpica tratada con ciclosporina A. A propósito de tres casos.